Chronic migraineurs who started GLP-1 drugs also were 14% less likely to be hospitalized (RR 0.86, 95% CI 0.81-0.91), and ...

In a move expected to benefit thousands of New Jersey residents living with obesity and type 2 diabetes, Novo Nordisk, whose U.S. headquarters is based in Plainsboro, announced it will significantly ...

Drugmaker Lilly said its experimental pill, orforglipron, produced better blood sugar and weight loss for diabetes patients results in a new head-to-head clinical trial.

Have you noticed the side effects listed for one of those new drugs being advertised on TV? It may seem as if one of those marvelous medicines might be a good solution for your problem, but the long ...

Have you noticed the side effects listed for one of those new drugs being advertised on TV? It may seem as if one of those marvelous medicines might be a good solution for your problem, but the long ...

A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...

Eli Lilly has spent months signaling it would challenge Novo Nordisk’s oral GLP-1 franchise. Now it has data to back that up.

Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but ...

Feb 26 () - Eli Lilly on Thursday released new data from a head-to-head trial of its experimental weight-loss ‌pill, ...

Eli Lilly (LLY) stock falls as rival Novo Nordisk (NVO) plans to cut Wegovy, Ozempic & Rybelsus U.S. list prices from Jan 1, 2027. Read more here.

For many young adults in India, the fastest route to shedding kilograms isn’t the gym—it’s a pill. Once prescribed for type 2 diabetes, drugs such as Rybelsus, ...